Profiling Critical Cancer Genes in Clinical Tumor Samples
Laura MacConaill, PhD presents the cumulative body of work at the Dana Farber Cancer Institute and Brigham and Women's Hospital during the conference at the Association for Molecular Pathology, November 2010.
View the online presentation to learn:
-
Why targeting cancer based on genetics is crucial
-
New genomic technologies that can aide in discovery vs. diagnostic analysis
-
About OncoMap for accelerated somatic mutation profiling
-
A vision for personalized cancer medicine now and in the future
Ultra sensitive mutation detection on the MassARRAY® system
Therapeutic research for biomarkers in new areas such as early treatment or residual disease requires highly sensitive detection methods. Analysis of blood and serum samples also require detection limits of <1%. A new application note demonstrates ultra-sensitive mutation detection using the MassARRAY system with SABER biochemistry. Find out more about the SABER method.
Rapid somatic mutation analysis–powered by Assays by Sequenom
-
Rapidly validate or profile somatic mutations in tumor samples
-
Select from our research use only OncoCarta™ family of >600 assays
-
Or send us your list by gene, pathway, or tissue
-
Let us design the assays and run your samples
-
No instrumentation or system required
Rapid, highly accurate DNA methylation profiling
The MassARRAY Analyzer 4 system offers a highly accurate, sensitive method for your epigenetic studies. It enables you to:
-
Design assays to profile any region or gene of interest
-
Analyze multiple CpGs in one simple reaction
-
Evaluate regions from 100 to 600 bp
-
Detect as little as 5% changes in methylation*
Leading institutions have used the 384-well system to identify important methylation status. The EpiTYPER™ 96 application will be available soon to run on the 96-well system. EpiTYPER 96 will offer an ideal format for your smaller studies.
Hypermethylation of Tumor Suppressor Genes Involved in Critical Regulatory Pathways for Developing a Blood-Based Test in Breast Cancer
This study evaluates the possibility of a blood-based test for analyzing the methylation of circulating cell-free DNA derived from tumor for the potential diagnosis and management of breast cancer patients. Using the EpiTYPER method, over 30k CpGs from ten breast cancer genes were rapidly profiled. Significant promoter hypermethylation of eight tumor suppressor genes was seen. The results suggest the potential of using cancer-specific methylation changes in plasma and serum for the development of a blood-based test as a predictive and prognostic biomarker.
Search our literature database for more key studies powered by the MassARRAY system.
|
Upcoming Events:
Name: AACR Annual Meeting
Date: April 2-6, 2011
Details: Come visit us at booth #215
|
|